Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company provides educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides distance learning residency preparatory courses; and develops and sells digital and printed medical content. As of December 31, 2020, it operated a network of 24 undergraduate and graduate medical school campuses consisted of 19 operating units and five approved units. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
IPO Year: 2019
Exchange: NASDAQ
Website: afya.com.br
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2025 | $19.00 → $17.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/31/2025 | $18.00 → $15.00 | Neutral → Sell | Citigroup |
| 12/3/2024 | $16.00 | Sell | Goldman |
| 8/30/2024 | $19.50 | Neutral | UBS |
| 1/29/2024 | $23.00 | Neutral | Citigroup |
| 1/22/2024 | $20.50 → $23.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $16.50 → $20.50 | Equal-Weight → Overweight | Morgan Stanley |
| 4/8/2022 | $18.00 → $19.00 | Neutral → Outperform | Credit Suisse |
| 3/7/2022 | $27.00 → $21.00 | Buy | UBS |
| 7/21/2021 | $28.50 | Overweight → Equal-Weight | Morgan Stanley |
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three-month period ended March 31, 2025 (first quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2025 Highlights 1Q25 Net Revenue increased 16.4% YoY to R$936.4 million. Net Revenue excluding acquisitions increased 10.9%, reaching R$891.5 million. 1Q25 Adjusted
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, in addition to the Press Release released by the company on December 19th, 2024, announced today the closing of its acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of Faculdade Masterclass Ltda. ("FACULDADE ÚNICA DE CONTAGEM" or "FUNIC"), located in Contagem, a city in the metropolitan area of Belo Horizonte, the capital of the State of Minas Gerais. The acquisition contributes 60 medical school seats to Afya. FUNIC is pre-operational, with leased real estate prepared for a medi
Impressive Adjusted EBITDA Margin Expansion Expressive Cash Generation First Dividend Announcement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2024. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2024 Highlights 4Q24 Net Revenue increased 16.3% YoY to R$849.0 million. Net Revenue excluding acquisitions increased 12.0%, reaching R$817.8 million. 4Q24 Adjust
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), Brazil's leading medical education group and provider of medical practice solutions, announced that its board of directors (the "Board") approved its first distribution of a cash dividend. On March 12, 2025, Afya's Board declared a cash dividend of R$129.8 million, representing 20% of the Company's consolidated net income of R$648.9 million for the year ended December 31, 2024. This amounts to a dividend per share (DPS) of R$1.348923, payable in U.S. dollars on April 4, 2025, to shareholders of record as of the close of business on March 26, 2025. The payment will be made at the exchange rate (PTAX) published on March 13, 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it has entered into a share purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of Faculdade Masterclass Ltda. ("Faculdade Única de Contagem" or "FUNIC"), present in Contagem (MG). The acquisition will add 60 medical school seats to Afya in Contagem, a city in the metropolitan area of Belo Horizonte, the capital of Minas Gerais. FUNIC is pre-operational, with leased real estate prepared for the start of the medical school operation. I
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that it will host its Afya Day on October 29th, 2024. The event will be held in a hybrid format, combining both in-person and online participation, and will feature presentations from Afya's executive team, covering the Company's growth, business strategy and future outlook. Event Details: Date: October 29th, 2024. Time: 9:00 a.m. to 12:00 p.m. (São Paulo time) & 8:00 a.m. to 11:00 a.m. (EST). Format: Hybrid (in-person and virtual participation) Location for in-person attendees: Afya's São Paulo Flagship, Alameda Lore
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced a public commitment to achieve 5 million free health consultations by 2030, in line with Sustainable Development Goal 3 (SDG 3), which aims to ensure healthy lives and promote well-being for all people, at all ages. To serve the communities and achieve the estimated results, Afya intends to increase to 27 the number of its own outpatient clinics that carry out medical consultations and health care in various specialties, such as psychology, physiotherapy, dentistry, among others. Currently, there are 20 outpatient clinics in di
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that following the conclusion of an administrative procedure, the Ministry of Education ("MEC"), has granted the request for reconsideration submitted by Universidade do Grande Rio Professor José de Souza Herdy ("Unigranrio"). Per the e-MEC portal, Unigranrio reestablished 10 medical seats in the city of Rio de Janeiro, reaching 318 medical seats across both Unigranrio campuses, contributing to Afya's 3,593 total approved medical seats. This seat reconsideration highlights our dedication to excellence in medical educatio
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
Morgan Stanley downgraded Afya from Equal-Weight to Underweight and set a new price target of $17.00 from $19.00 previously
Citigroup downgraded Afya from Neutral to Sell and set a new price target of $15.00 from $18.00 previously
Goldman initiated coverage of Afya with a rating of Sell and set a new price target of $16.00
UBS initiated coverage of Afya with a rating of Neutral and set a new price target of $19.50
Citigroup initiated coverage of Afya with a rating of Neutral and set a new price target of $23.00
Morgan Stanley downgraded Afya from Overweight to Equal-Weight and set a new price target of $23.00 from $20.50 previously
Morgan Stanley upgraded Afya from Equal-Weight to Overweight and set a new price target of $20.50 from $16.50 previously
Credit Suisse upgraded Afya from Neutral to Outperform and set a new price target of $19.00 from $18.00 previously
UBS reiterated coverage of Afya with a rating of Buy and set a new price target of $21.00 from $27.00 previously
Morgan Stanley downgraded Afya from Overweight to Equal-Weight and set a new price target of $28.50
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
20-F - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
SCHEDULE 13D/A - Afya Ltd (0001771007) (Subject)
SCHEDULE 13G/A - Afya Ltd (0001771007) (Subject)
SCHEDULE 13D/A - Afya Ltd (0001771007) (Subject)
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three-month period ended March 31, 2025 (first quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2025 Highlights 1Q25 Net Revenue increased 16.4% YoY to R$936.4 million. Net Revenue excluding acquisitions increased 10.9%, reaching R$891.5 million. 1Q25 Adjusted
Impressive Adjusted EBITDA Margin Expansion Expressive Cash Generation First Dividend Announcement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2024. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2024 Highlights 4Q24 Net Revenue increased 16.3% YoY to R$849.0 million. Net Revenue excluding acquisitions increased 12.0%, reaching R$817.8 million. 4Q24 Adjust
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), Brazil's leading medical education group and provider of medical practice solutions, announced that its board of directors (the "Board") approved its first distribution of a cash dividend. On March 12, 2025, Afya's Board declared a cash dividend of R$129.8 million, representing 20% of the Company's consolidated net income of R$648.9 million for the year ended December 31, 2024. This amounts to a dividend per share (DPS) of R$1.348923, payable in U.S. dollars on April 4, 2025, to shareholders of record as of the close of business on March 26, 2025. The payment will be made at the exchange rate (PTAX) published on March 13, 2
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and six-month period, which ended on June 30, 2024 (second quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second Quarter 2024 Highlights 2Q24 Net Revenue increased 13.7% YoY to R$809.9 million. 2Q24 Adjusted EBITDA increased 28.2% YoY reaching R$343.8 million, with an Adjus
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2024 (first quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2024 Highlights 1Q24 Net Revenue increased 13.3% YoY to R$804.2 million. 1Q24 Adjusted EBITDA increased 20.5% YoY reaching R$397.9 million, with an Adjusted EBITDA Margin of
Another Year of Strong Performance Robust EPS Expansion Guidance Achievement Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the fourth quarter and full-year period ended December 31, 2023. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2023 Highlights 4Q23 Adjusted Net Revenue increased 22.6% YoY to R$729.5 million. Adjusted Net Revenue excluding acquisitions grew 12.5% to R$669.7 million. 4Q23 Adjusted EBITDA increased 1
Guidance on Track Strong Cash Conversion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the three and nine-month period ended September 30, 2023. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2023 Highlights 3Q23 Adjusted Net Revenue increased 24.6% YoY to R$723.0 million. Adjusted Net Revenue excluding acquisitions grew 13.6%, reaching R$659.0 million. 3Q23 Adjusted EBITDA increased 21.7% YoY, reaching R$278.4 million, w
Afya Limited, or "Afya" (NASDAQ:AFYA, B3: A2FY34))) announced today that will report third-quarter and nine months 2023 financial results for the period ended September 30th, 2023, following the close of the market on Monday, November 13th, 2023 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.afya.com.br/. To participate in Afya's Third Quarter and Nine Months 2023 conference call, please follow the instructions below: Webcast: https://afya.zoom.us/j/97410751315 Dial-in: Brazil: +55 11 4632 2236 or +55 11 4632 2237 or +55 11